A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate long-term safety and tolerability of JNS001 at
18 to 72 mg per day in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).